DREAM: Phase II Trial of First-line Combination Durvalumab Plus Chemotherapy in Advanced Mesothelioma

Source: 2018 American Society of Clinical Oncology Annual Meeting*
Download Slideset
June 1-5, 2018; Chicago, Illinois
In preliminary results, first-line combination chemoimmunotherapy with durvalumab achieved an ORR of 58% and 6-month PFS of 65% in advanced MPM.
Format: Microsoft PowerPoint (.ppt)
File Size: 193 KB
Released: June 6, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Download these slides for an overview of the evolving immunotherapy landscape for advanced or metastatic NSCLC, from CCO

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Download these slides for an overview of the evolving immunotherapy landscape for early-stage resectable and stage III unresectable NSCLC, from CCO

person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Results from phase III ATLANTIS trial of lurbinectedin plus doxorubicin in patients with relapsed small-cell lung cancer (SCLC), from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 17, 2021

CheckMate 9LA analysis of nivolumab plus ipilimumab plus chemotherapy in advanced NSCLC with brain metastases, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue